The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines

Triple-negative breast cancers are particularly aggressive. In vitro cultures are one of the major pathways for developing anticancer strategies. The effectiveness and reproducibility of the drug screenings depend largely on the homogeneity of culture media. In order to optimize the predictive respo...

Full description

Bibliographic Details
Main Authors: Clémence Dubois, Pierre Daumar, Corinne Aubel, Jean Gauthier, Bernard Vidalinc, Emmanuelle Mounetou, Frédérique Penault-Llorca, Mahchid Bamdad
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:Journal of Clinical Medicine
Subjects:
synthetic medium OptiPASS
triple negative breast cancer
MDA-MB-231
SUM1315
spheroid development
drug screening
Online Access:https://www.mdpi.com/2077-0383/8/3/397
id doaj-76bb8035426048e796afe57bcf09fef5
record_format Article
spelling doaj-76bb8035426048e796afe57bcf09fef52020-11-24T20:53:58ZengMDPI AGJournal of Clinical Medicine2077-03832019-03-018339710.3390/jcm8030397jcm8030397The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell LinesClémence Dubois0Pierre Daumar1Corinne Aubel2Jean Gauthier3Bernard Vidalinc4Emmanuelle Mounetou5Frédérique Penault-Llorca6Mahchid Bamdad7Institut Universitaire de Technologie, Université Clermont Auvergne, INSERM, U1240, Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont Ferrand, FranceInstitut Universitaire de Technologie, Université Clermont Auvergne, INSERM, U1240, Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont Ferrand, FranceFaculté de médecine, Université Clermont Auvergne, INSERM, U1240, Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont Ferrand, FranceBiomarqueurs S.A.S, F-63200 Riom, FranceBiomarqueurs S.A.S, F-63200 Riom, FranceInstitut Universitaire de Technologie, Université Clermont Auvergne, INSERM, U1240, Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont Ferrand, FranceCentre Jean Perrin, Université Clermont Auvergne, INSERM, U1240, Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont Ferrand, FranceInstitut Universitaire de Technologie, Université Clermont Auvergne, INSERM, U1240, Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont Ferrand, FranceTriple-negative breast cancers are particularly aggressive. In vitro cultures are one of the major pathways for developing anticancer strategies. The effectiveness and reproducibility of the drug screenings depend largely on the homogeneity of culture media. In order to optimize the predictive responses of triple-negative breast cancer 3D cell culture models, these works were focused on the development of SUM1315 and MDA-MB-231 cell lines in OptiPASS medium, a new serum-free formulation (BIOPASS). In monolayer cell culture, OptiPASS medium was more suitable for MDA-MB-231 than SUM1315 cell line but maintained cell phenotype and allowed sufficient proliferation. For spheroids produced in OptiPASS, the size monitoring showed a 1.3 and 1.5-fold increase for MDA-MB-231 and SUM1315 cell lines, respectively and viability/mortality profiles were maintained. Spheroids drug sensitivity thresholds were also improved allowing quicker high throughput drug screenings. These results showed the suitability of OptiPASS for 2D and 3D cell cultures of these two triple-negative breast cancer cell lines, with reproducibility of spheroid formation superior to 98%. This opens the way to the common use of this synthetic medium in future preclinical breast cancer research studies.https://www.mdpi.com/2077-0383/8/3/397synthetic medium OptiPASStriple negative breast cancerMDA-MB-231SUM1315spheroid developmentdrug screening
collection DOAJ
language English
format Article
sources DOAJ
author Clémence Dubois
Pierre Daumar
Corinne Aubel
Jean Gauthier
Bernard Vidalinc
Emmanuelle Mounetou
Frédérique Penault-Llorca
Mahchid Bamdad
spellingShingle Clémence Dubois
Pierre Daumar
Corinne Aubel
Jean Gauthier
Bernard Vidalinc
Emmanuelle Mounetou
Frédérique Penault-Llorca
Mahchid Bamdad
The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
Journal of Clinical Medicine
synthetic medium OptiPASS
triple negative breast cancer
MDA-MB-231
SUM1315
spheroid development
drug screening
author_facet Clémence Dubois
Pierre Daumar
Corinne Aubel
Jean Gauthier
Bernard Vidalinc
Emmanuelle Mounetou
Frédérique Penault-Llorca
Mahchid Bamdad
author_sort Clémence Dubois
title The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
title_short The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
title_full The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
title_fullStr The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
title_full_unstemmed The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
title_sort new synthetic serum-free medium optipass promotes high proliferation and drug efficacy prediction on spheroids from mda-mb-231 and sum1315 triple-negative breast cancer cell lines
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2019-03-01
description Triple-negative breast cancers are particularly aggressive. In vitro cultures are one of the major pathways for developing anticancer strategies. The effectiveness and reproducibility of the drug screenings depend largely on the homogeneity of culture media. In order to optimize the predictive responses of triple-negative breast cancer 3D cell culture models, these works were focused on the development of SUM1315 and MDA-MB-231 cell lines in OptiPASS medium, a new serum-free formulation (BIOPASS). In monolayer cell culture, OptiPASS medium was more suitable for MDA-MB-231 than SUM1315 cell line but maintained cell phenotype and allowed sufficient proliferation. For spheroids produced in OptiPASS, the size monitoring showed a 1.3 and 1.5-fold increase for MDA-MB-231 and SUM1315 cell lines, respectively and viability/mortality profiles were maintained. Spheroids drug sensitivity thresholds were also improved allowing quicker high throughput drug screenings. These results showed the suitability of OptiPASS for 2D and 3D cell cultures of these two triple-negative breast cancer cell lines, with reproducibility of spheroid formation superior to 98%. This opens the way to the common use of this synthetic medium in future preclinical breast cancer research studies.
topic synthetic medium OptiPASS
triple negative breast cancer
MDA-MB-231
SUM1315
spheroid development
drug screening
url https://www.mdpi.com/2077-0383/8/3/397
work_keys_str_mv AT clemencedubois thenewsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT pierredaumar thenewsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT corinneaubel thenewsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT jeangauthier thenewsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT bernardvidalinc thenewsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT emmanuellemounetou thenewsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT frederiquepenaultllorca thenewsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT mahchidbamdad thenewsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT clemencedubois newsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT pierredaumar newsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT corinneaubel newsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT jeangauthier newsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT bernardvidalinc newsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT emmanuellemounetou newsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT frederiquepenaultllorca newsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
AT mahchidbamdad newsyntheticserumfreemediumoptipasspromoteshighproliferationanddrugefficacypredictiononspheroidsfrommdamb231andsum1315triplenegativebreastcancercelllines
_version_ 1716795622441353216

Similar Items